HASHEM EL-SERAG to Adenocarcinoma
This is a "connection" page, showing publications HASHEM EL-SERAG has written about Adenocarcinoma.
Connection Strength
8.088
-
Why Has Screening and Surveillance for Barrett's Esophagus Fallen Short in Stemming the Rising Incidence of Esophageal Adenocarcinoma? Am J Gastroenterol. 2023 04 01; 118(4):590-592.
Score: 0.489
-
Current Status of Chemoprevention in Barrett's Esophagus. Gastrointest Endosc Clin N Am. 2021 Jan; 31(1):117-130.
Score: 0.421
-
External Validation of the Michigan Barrett's Esophagus Prediction Tool. Clin Gastroenterol Hepatol. 2017 07; 15(7):1124-1126.
Score: 0.327
-
The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus. Am J Gastroenterol. 2017 Jul; 112(7):1049-1055.
Score: 0.327
-
Sex and Racial Disparity in Incidence of Esophageal Adenocarcinoma: Observations and Explanations. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):330-2.
Score: 0.298
-
Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett's oesophagus. Gut. 2016 08; 65(8):1252-60.
Score: 0.294
-
Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett's esophagus: a nested case-control study. Gastroenterology. 2015 Nov; 149(6):1392-8.
Score: 0.292
-
Esophageal carcinoma. N Engl J Med. 2015 04 09; 372(15):1472-3.
Score: 0.286
-
Esophageal carcinoma. N Engl J Med. 2014 Dec 25; 371(26):2499-509.
Score: 0.281
-
The incidence of esophageal adenocarcinoma in a national veterans cohort with Barrett's esophagus. Am J Gastroenterol. 2014 Dec; 109(12):1862-8; quiz 1861, 1869.
Score: 0.277
-
Risk of upper gastrointestinal cancers in patients with gastroesophageal reflux disease after a negative screening endoscopy. Clin Gastroenterol Hepatol. 2015 Feb; 13(2):280-6.
Score: 0.272
-
Decision aids for shared decision-making in Barrett's esophagus surveillance. Clin Gastroenterol Hepatol. 2015 Jan; 13(1):91-3.
Score: 0.269
-
Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut. 2014 Aug; 63(8):1229-37.
Score: 0.260
-
Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Dig Dis Sci. 2010 Dec; 55(12):3404-7.
Score: 0.203
-
Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology. 2010 Jun; 138(7):2260-6.
Score: 0.201
-
Alcohol drinking and the risk of Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology. 2009 Apr; 136(4):1155-7.
Score: 0.187
-
Phase I and II enzyme polymorphisms as risk factors for Barrett's esophagus and esophageal adenocarcinoma: a systematic review and meta-analysis. Dis Esophagus. 2009; 22(7):571-87.
Score: 0.187
-
Secular trends in the use, quality, and outcomes of gastrectomy for noncardia gastric cancer in the United States. Ann Surg Oncol. 2007 Sep; 14(9):2519-27.
Score: 0.167
-
Noncardia gastric adenocarcinoma remains an important and deadly cancer in the United States: secular trends in incidence and survival. Am J Gastroenterol. 2006 Nov; 101(11):2485-92.
Score: 0.159
-
The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther. 2006 Jul 01; 24(1):87-94.
Score: 0.156
-
Emergency Presentations Predict Worse Outcomes Among Patients with Pancreatic Cancer. Dig Dis Sci. 2024 Feb; 69(2):603-614.
Score: 0.131
-
The Impact of Race on Pancreatic Cancer Treatment and Survival in the Nationwide Veterans Affairs Healthcare System. Pancreas. 2024 Jan 01; 53(1):e27-e33.
Score: 0.130
-
Diabetes Status and Pancreatic Cancer Survival in the Nationwide Veterans Affairs Healthcare System. Dig Dis Sci. 2023 09; 68(9):3634-3643.
Score: 0.127
-
Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol. 2003 Jul; 98(7):1627-33.
Score: 0.127
-
Risk of gastric and oesophageal adenocarcinoma following discontinuation of long-term proton-pump inhibitor therapy. J Gastroenterol. 2022 12; 57(12):942-951.
Score: 0.121
-
Missed Opportunities for Screening or Surveillance Among Patients with Newly Diagnosed Non-cardia Gastric Adenocarcinoma. Dig Dis Sci. 2023 03; 68(3):761-769.
Score: 0.118
-
The epidemic of esophageal adenocarcinoma. Gastroenterol Clin North Am. 2002 Jun; 31(2):421-40, viii.
Score: 0.118
-
Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut. 2002 Mar; 50(3):368-72.
Score: 0.115
-
External validation of a model determining risk of neoplastic progression of Barrett's esophagus in a cohort of U.S. veterans. Gastrointest Endosc. 2022 06; 95(6):1113-1122.
Score: 0.114
-
Prevalence and Predictors of Missed Dysplasia on Index Barrett's Esophagus Diagnosing Endoscopy in a Veteran Population. Clin Gastroenterol Hepatol. 2022 04; 20(4):e876-e889.
Score: 0.109
-
Segment length and risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med. 2000 Nov 07; 133(9):747-8.
Score: 0.105
-
Systematic review with meta-analysis: prevalence of prior and concurrent Barrett's oesophagus in oesophageal adenocarcinoma patients. Aliment Pharmacol Ther. 2020 07; 52(1):20-36.
Score: 0.102
-
Prevalence of Helicobacter pylori Positive Non-cardia Gastric Adenocarcinoma Is Low and Decreasing in a US Population. Dig Dis Sci. 2020 08; 65(8):2403-2411.
Score: 0.098
-
Missed Opportunities for Screening and Surveillance of Barrett's Esophagus in Veterans with Esophageal Adenocarcinoma. Dig Dis Sci. 2019 02; 64(2):367-372.
Score: 0.092
-
Prior Diagnosis of Barrett's Esophagus Is Infrequent, but Associated with Improved Esophageal Adenocarcinoma Survival. Dig Dis Sci. 2018 11; 63(11):3112-3119.
Score: 0.090
-
Underuse of Surgery Accounts for Racial Disparities in Esophageal Cancer Survival Times: A Matched Cohort Study. Clin Gastroenterol Hepatol. 2019 03; 17(4):657-665.e13.
Score: 0.090
-
Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans. Aliment Pharmacol Ther. 2018 08; 48(4):469-477.
Score: 0.090
-
The Association Between Statin Use After Diagnosis and Mortality Risk in Patients With Esophageal Cancer: A Retrospective Cohort Study of United States Veterans. Am J Gastroenterol. 2018 09; 113(9):1310.
Score: 0.089
-
Helicobacter pylori Infection Is Associated With Reduced Risk of Barrett's Esophagus: An Analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Am J Gastroenterol. 2018 08; 113(8):1148-1155.
Score: 0.089
-
Risk of oesophageal adenocarcinoma in individuals with Barrett's oesophagus. Eur J Cancer. 2017 04; 75:41-46.
Score: 0.081
-
Opportunities for Preventing Esophageal Adenocarcinoma. Cancer Prev Res (Phila). 2016 Nov; 9(11):828-834.
Score: 0.079
-
Esophageal adenocarcinoma after obesity surgery in a population-based cohort study. Surg Obes Relat Dis. 2017 Jan; 13(1):28-34.
Score: 0.074
-
Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. Gastroenterology. 2015 Nov; 149(6):1599-606.
Score: 0.073
-
Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013 Nov; 11(11):1399-1412.e7.
Score: 0.063
-
Incidence and survival of colorectal cancer among Hispanics in the United States: a population-based study. Dig Dis Sci. 2013 Jul; 58(7):2052-60.
Score: 0.060
-
Surveillance in Barrett's esophagus: lessons from behavioral economics. Gastroenterology. 2009 Sep; 137(3):763-5.
Score: 0.048
-
Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008 Mar; 67(3):394-8.
Score: 0.043
-
Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005 Aug 02; 143(3):199-211.
Score: 0.037
-
Barrett's esophagus, hiatal hernia, and logistic regression analysis. Am J Gastroenterol. 1999 Dec; 94(12):3395-6.
Score: 0.025
-
Opposing time trends of peptic ulcer and reflux disease. Gut. 1998 Sep; 43(3):327-33.
Score: 0.023
-
Menopausal hormone therapy and the risk of esophageal and gastric cancer. Int J Cancer. 2017 04 01; 140(7):1693-1699.
Score: 0.020
-
Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus. Am J Gastroenterol. 2016 11; 111(11):1528-1535.
Score: 0.020
-
Weight Change and Weight Cycling Are?Not?Associated With Risk of Barrett's?Esophagus. Clin Gastroenterol Hepatol. 2016 12; 14(12):1839-1840.
Score: 0.019
-
Patients' intuitive judgments about surveillance endoscopy in Barrett's esophagus: a review and application to models of decision-making. Dis Esophagus. 2013 Sep-Oct; 26(7):682-9.
Score: 0.015